33
Participants
Start Date
September 30, 2011
Primary Completion Date
December 31, 2013
Study Completion Date
November 30, 2014
TKI258 (Dovitinib):
TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
Department of Internal Medicine, Seoul National University Hospital, Seoul
Seoul National University Hospital
OTHER